NEW YORK (GenomeWeb) – IncellDx and Celsee Diagnostics announced today that they have partnered to test the combination of their respective protein expression analysis and rare cell isolation technologies for predicting patient responses to metastatic lung cancer immunotherapy.
Under the terms of the deal, the companies will perform IncellDx's OncoTect iO quantitative assay for PD-L1 expression on peripheral blood samples obtained from metastatic lung cancer patients using Celsee's single-cell isolation and analysis platforms. The results will then be compared with OncoTect iO data from primary tumors tissue dissociated with IncellDx's IncellPrep kit. This analysis will be used to tailor cancer therapy to more closely address clones capable of spreading, and could potentially be used with additional cancer types, the companies said.
Additional terms of the deal were not disclosed.
"Immunotherapy shows great promise for the treatment of specific types of metastatic cancer," Celsee CEO Kalyan Handique said in a statement. "This collaborative study will continue to validate the use of the Celsee Prep platform for detecting a wide range of surface biomarkers on rare cells in the blood, and substantiate the value of the platform for use in prognosis and therapeutic decision making."
IncellDx CEO Bruce Patterson added that his company's platform could potentially expand applications for Celsee's Prep platform from blood to rare-event detection in primary tumors.